3-MeO-PCP

3-MeO-PCP
Chemical Nomenclature
Common names	3-MeO-PCP, 3-MeO
Substitutive name	3-Methoxyphencyclidine
Systematic name	1-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine
Class Membership
Psychoactive class	Dissociative
Chemical class	Arylcyclohexylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Smoked Dosage Threshold 2 mg Light 5 - 10 mg Common 10 - 20 mg Strong 20 - 25 mg Heavy 25 mg + Heavy doses may result in psychosis and mania. Duration Total 45 - 120 minutes ⇣ Oral Dosage Threshold 2 mg Light 4 - 8 mg Common 8 - 15 mg Strong 15 - 25 mg Heavy 25 mg + Heavy doses may result in psychosis and mania. Duration Total 4 - 8 hours Onset 30 - 90 minutes Come up 45 - 120 minutes Peak 2 - 3 hours Offset 1 - 2 hours After effects 4 - 48 hours ⇣ Insufflated Dosage Threshold 1 mg Light 2 - 5 mg Common 5 - 10 mg Strong 10 - 15 mg Heavy 15 mg + Heavy doses may result in psychosis and mania. Duration Total 3 - 5 hours Onset 5 - 30 minutes Come up 45 - 90 minutes Peak 1.5 - 2 hours Offset 45 - 60 minutes After effects 4 - 48 hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
Stimulants
Depressants

Summary sheet: 3-MeO-PCP

3-MeO-PCP (3-Methoxyphencyclidine) is a chemical of the arylcyclohexylamine class which acts as a hallucinogenic dissociative.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency. Today it is used as a recreational drug and an entheogen, rarely sold on the streets and almost exclusively obtained as a grey area research chemical through the use of online vendors.

Chemistry

3-MeO-PCP, or 3-Methoxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. 4-MeO-PCP contains cyclohexane, a six member saturated ring, bonded to two additional rings at R₁. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at it's nitrogen group. The other ring is an aromatic phenyl ring, substituted at R₃ with a methoxy group. 3-MeO-PCP is a PCP derivative, and structurally analogous to 4-MeO-PCP.

Pharmacology

Main article: NMDA receptor antagonist

3-MeO-PCP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. NMDA receptor antagonists close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole”.

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. Though 3-MeO-PCP is often described as having opioid or dopaminergic activity, this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter. 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a research chemical in 2011.

Subjective effects

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

• Increased heart rate
• Tactile disconnection
• Spontaneous tactile sensations
• Tactile enhancement and Tactile suppression
• Bodily control enhancement and Motor control loss
• Stimulation
• Physical autonomy
• Motor control loss
• Physical euphoria
• Perception of decreased weight
• Dizziness
• Nausea
• Visual sliding

Cognitive effects

• Depersonalization
• Derealization
• Consciousness disconnection
• Memory suppression
  • Ego death
• Thought deceleration
• Immersion enhancement
• Information processing suppression
• Time distortion
• Euphoria
• Introspection
• Déjà vu
• Conceptual thinking
• Unity and interconnectedness
• Compulsive redosing
• Anxiety suppression
• Disinhibition
• Amnesia
• Feelings of impending doom
• Creativity enhancement

Enhancements

• Colour enhancement
• Acuity enhancement

Suppressions

• Visual disconnection - This eventually results in 3-MeO-PCP's equivalent of the famous "k-hole" or more specifically, holes, spaces and voids alongside of structures.
• Visual acuity suppression
• Double vision
• Pattern recognition suppression
• Frame rate suppression

Distortions

• Perspective distortions
• Environmental cubism
• Environmental orbism
• Scenery slicing

Hallucinatory states

• Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)

Auditory effects

• Suppression
• Distortions
• Hallucinations

Toxicity and harm potential

The toxicity and long-term health effects of recreational 3-MeO-PCP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-MeO-PCP has very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCP within the community confirm that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself or using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of 3-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.

Tolerance to many of the effects of 3-MeO-PCP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Note that 3-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of 3-MeO-PCP, all dissociatives will have a reduced effect.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:

• Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
• Urinary urgency - This can be described as a sudden, compelling need to urinate.
• Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
• Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
• Hematuria - Hematuria is visible blood in the urine.
• Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 3-MeO-PCP on a daily or even weekly basis and manually limiting one's usage of the substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
• Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• UK - On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.
• Sweden - Sweden's public health agency suggested classifying 3-MeO-PCP as hazardous substance on November 10, 2014.
• Germany - On November 21, 2015 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.

See also

• 4-MeO-PCP
• PCP
• Dissociatives
• Arylcyclohexylamines

External links

• 3-MeO-PCP (Wikipedia)
• 3-MeO-PCP experiences (Erowid)
• 3-MeO-PCP (Bluelight)
• 3-MeO-PCP (Tripsit)